Format

Send to

Choose Destination
Am J Hematol. 2018 Feb;93(2):238-245. doi: 10.1002/ajh.24964. Epub 2017 Nov 21.

Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults.

Author information

1
Division of Hematology/Oncology, Department of Pediatrics, Children's of Alabama/University of Alabama at Birmingham, Birmingham, Alabama.
2
Division of Hematology, Department of Medicine, The Ohio State University, Ohio.
3
Division of Hematology/Oncology, Department of Pediatrics, Children's Hospital of Michigan/Wayne State University School of Medicine, Detroit, Michigan.
4
Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.
5
Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.

Abstract

Adolescents and young adults (AYA) surviving classical Hodgkin lymphoma (cHL) risk long term fatal treatment-related toxicities. We utilized the Surveillance, Epidemiology and End Results (SEER) program to compare excess mortality rate (EMR-observed minus expected mortality) for 10-year survivors of AYA cHL diagnosed in 1973-1992 and 1993-2003 eras. The 15-year EMR reduced from 4.88% to 2.19% while the 20-year EMR reduced from 9.46% to 4.07% between eras. Survivors of stages 1-2 had lower EMR than survivors of stages 3-4 cHL in the 1993-2003 but not in the 1973-1992 era. There was an overall decline in risk of death between 10 and 15 years from diagnosis, driven mostly by second neoplasms and cardiovascular mortality. Despite reduction in fatal second neoplasms and cardiovascular disease with more current therapy, long term survivors of AYA cHL still have a higher risk of death than the general population highlighting the need for safer therapies.

PMID:
29114948
DOI:
10.1002/ajh.24964

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center